The company offers proprietary genomic, epigenetic, and other molecular technologies that assist physicians in diagnosing urologic cancers, predicting recurrence risk, and determining response to specific therapies. MDxHealth generates revenue through clinical laboratory service testing or the out-licensing of its patented DNA methylation platform and biomarkers. The company operates in Europe and the United States, with headquarters in Belgium and California.